HBV vaccine and risk of developing multiple sclerosis: a systematic review and meta-analysis

Figures & data

Figure 1. Flow-chart of search strategy

Table 1. Characteristics of included studies

First Author	Country	Year	Study design	Sample Size	Mean Age	Events	NOS(max 9)
Ascherio^Citation17	France	2001	Nested Case control	192 cases and 645 controls	37.6 y	32 (cases) 84 (controls)	7
Efetekarian^Citation18	Iran	2015	Case control	250 cases 250 controls	33 y	101 (cases) 149 (controls)	2
Hernan^Citation19	Usa	2004	Case control	163 cases 1604 controls	NR	11 (cases) 152 (controls)	8
Langer Gould^Citation20	Usa	2014	Case control	43 cases 249 controls	39.3 y	18 (cases) 762 (controls)	7
Mikaeloff^Citation21	France	2007	Case Control	143 cases 1122 controls	11 y	80 (cases) 63 (controls)	7
Ramagoplan^Citation22	Canada	2009	Case control	14,362 cases 7671 controls	49 y	12,330 (cases) 2032 (controls)	6
Touzè^Citation23	France	2002	Case control	236 cases 355 controls	NR	9 (cases) 118(controls)	8

Table 2. Newcastle Ottawa Scale for included studies

	SELECTION					EXPOSURE
	Is the case definition adequate?	Representativeness of the cases	Selection of controls	Definition of controls	COMPARABILITY	Ascertainment of exposure	Same method of ascertainement for cases and controls	Non response rate	Total score (max 9 stars)
Ascherio	1	1	1	1	2	0	1	0	7
Eftekarian	0	0	0	0	2	0	0	0	2
Hernan	1	1	1	1	2	0	1	1	8
Langer-Gould	1	1	1	0	2	0	1	1	7
Mikaeloff	1	1	1	1	2	0	1	0	7
Ramagoplan	1	0	1	1	2	0	1	0	6
Touze	1	1	1	1	2	1	1	0	8

Figure 2. Crude risk estimate following Hepatitis B vaccination

Table 3. Meta regression analysis

	O.R.
Variables	Beta (p)
Year of publication	−0,019 8(0.001)
NOS	1,211 (<0.001)
Europe	0,063 (<0.001)
R^Citation2 0.974

Figure 3. Adjusted risk estimates following HBV vaccination

Figure 4. Funnel Plot

Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344(5):327–332. doi:10.1056/NEJM200102013440502.

 PubMed Web of Science ®Google Scholar

Eftekharian MM, Mousavi M, Hormoz MB, Roshanaei G, Mazdeh M. Multiple sclerosis and immunological-related risk factors: results from a case-control study. Human Antibodies. 2015;23(1,2):31–36.

 Google Scholar

Hernán MA, S S J, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63(5):838–842.

 PubMed Web of Science ®Google Scholar

Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, Sy LS, Chao C, Hechter R, Tseng HF. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA neurol. 2014;71(12):1506–1513. doi:10.1001/jamaneurol.2014.2633.

 PubMed Web of Science ®Google Scholar

Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med. 161(12):1176–1182. doi:10.1001/archpedi.161.12.1176.

 PubMedGoogle Scholar

Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Yee IM, Giovannoni G. Ebers GC Group Canadian Collaborative Study. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology. 2009;32(4):257–262. doi:10.1159/000201564.

 PubMed Web of Science ®Google Scholar

Touzé E, Fourrier A, Rue-Fenouche C, Rondé-Oustau V, Jeantaud I, Bégaud B, Alpérovitch A. Vaccination and first central nervous system demyelinating event: acase-control study. Neuroepidemiology. 2002;21(4):180–186.

 PubMed Web of Science ®Google Scholar

A S L, McMahon BJ. Chronic Hepatitis B. Hepatology. 2007;45(25):507–539. doi:10.1002/hep.21513.

 PubMed Web of Science ®Google Scholar